(CENT) Central Garden & Pet - Overview
Stock: Pet Accessories, Aquatic Supplies, Garden Seeds, Fertilizers, Wild-Bird Feed
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 34.5% |
| Relative Tail Risk | -14.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.12 |
| Alpha | -8.35 |
| Character TTM | |
|---|---|
| Beta | 0.583 |
| Beta Downside | 0.298 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.77% |
| CAGR/Max DD | 0.11 |
Description: CENT Central Garden & Pet January 13, 2026
Central Garden & Pet Company (NASDAQ:CENT) designs, manufactures, and distributes a broad portfolio of lawn-and-garden and pet-care products across the United States, operating through two distinct segments: Pet and Garden.
The Pet segment, which accounts for roughly 70 % of total revenue, offers dog and cat treats, toys, bedding, grooming supplies, waste-management products, as well as specialty items for aquatics, small animals, reptiles, birds, equine, and livestock. Core brands include Aqueon, Kaytee, K&H Pet Products, Nylabone, and Zilla.
The Garden segment, contributing about 30 % of revenue, supplies grass and vegetable seed, flower and herb packets, bird feed and accessories, fertilizers, decorative items, live plants, and a range of herbicides, insecticides, and pesticides under the Amdro, Ferry-Morse, Pennington, and Sevin names.
Products reach consumers via independent distributors, big-box retailers, national and regional chains, e-commerce platforms, grocery stores, nurseries, and mass-merchant outlets, with e-commerce now representing roughly 15 % of sales and growing at double-digit rates year-over-year.
Key performance indicators from the most recent fiscal year show total net sales of approximately $2.1 billion, a pet-segment gross margin of 42 % versus 35 % for garden, and an operating cash flow conversion of 85 %. The business is sensitive to discretionary-spending trends, raw-material cost inflation (particularly for fertilizers and pet-food ingredients), and the ongoing “human-of-the-pet” premiumization wave that has driven a 12 % CAGR in pet treat volumes over the past three years.
For a deeper, data-driven valuation, you might explore ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 162.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -2.03 > 1.0 |
| NWC/Revenue: 45.94% < 20% (prev 42.85%; Δ 3.09% < -1%) |
| CFO/TA 0.09 > 3% & CFO 332.5m > Net Income 162.8m |
| Net Debt (557.8m) to EBITDA (352.8m): 1.58 < 3 |
| Current Ratio: 3.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.4m) vs 12m ago -6.60% < -2% |
| Gross Margin: 31.87% > 18% (prev 0.29%; Δ 3158 % > 0.5%) |
| Asset Turnover: 87.88% > 50% (prev 91.55%; Δ -3.68% > 0%) |
| Interest Coverage Ratio: 4.64 > 6 (EBITDA TTM 352.8m / Interest Expense TTM 57.7m) |
Altman Z'' 4.54
| A: 0.40 (Total Current Assets 1.98b - Total Current Liabilities 538.8m) / Total Assets 3.63b |
| B: 0.28 (Retained Earnings 1.02b / Total Assets 3.63b) |
| C: 0.08 (EBIT TTM 267.9m / Avg Total Assets 3.56b) |
| D: 0.50 (Book Value of Equity 1.01b / Total Liabilities 2.04b) |
| Altman-Z'' Score: 4.54 = AA |
Beneish M -3.15
| DSRI: 1.02 (Receivables 325.3m/326.2m, Revenue 3.13b/3.20b) |
| GMI: 0.92 (GM 31.87% / 29.23%) |
| AQI: 1.00 (AQ_t 0.29 / AQ_t-1 0.29) |
| SGI: 0.98 (Revenue 3.13b / 3.20b) |
| TATA: -0.05 (NI 162.8m - CFO 332.5m) / TA 3.63b) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
What is the price of CENT shares?
Over the past week, the price has changed by +12.30%, over one month by +17.73%, over three months by +21.45% and over the past year by -5.40%.
Is CENT a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CENT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46 | 21.1% |
| Analysts Target Price | 46 | 21.1% |
| ValueRay Target Price | 37.5 | -1.2% |
CENT Fundamental Data Overview February 02, 2026
P/E Forward = 11.8343
P/S = 0.6728
P/B = 1.3302
P/EG = 2.56
Revenue TTM = 3.13b USD
EBIT TTM = 267.9m USD
EBITDA TTM = 352.8m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 56.9m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 557.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.66b USD (2.11b + Debt 1.44b - CCE 882.5m)
Interest Coverage Ratio = 4.64 (Ebit TTM 267.9m / Interest Expense TTM 57.7m)
EV/FCF = 9.15x (Enterprise Value 2.66b / FCF TTM 291.1m)
FCF Yield = 10.93% (FCF TTM 291.1m / Enterprise Value 2.66b)
FCF Margin = 9.30% (FCF TTM 291.1m / Revenue TTM 3.13b)
Net Margin = 5.20% (Net Income TTM 162.8m / Revenue TTM 3.13b)
Gross Margin = 31.87% ((Revenue TTM 3.13b - Cost of Revenue TTM 2.13b) / Revenue TTM)
Gross Margin QoQ = 28.98% (prev 34.55%)
Tobins Q-Ratio = 0.73 (Enterprise Value 2.66b / Total Assets 3.63b)
Interest Expense / Debt = 1.00% (Interest Expense 14.4m / Debt 1.44b)
Taxrate = 24.35% (52.8m / 216.8m)
NOPAT = 202.6m (EBIT 267.9m * (1 - 24.35%))
Current Ratio = 3.67 (Total Current Assets 1.98b / Total Current Liabilities 538.8m)
Debt / Equity = 0.91 (Debt 1.44b / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = 1.58 (Net Debt 557.8m / EBITDA 352.8m)
Debt / FCF = 1.92 (Net Debt 557.8m / FCF TTM 291.1m)
Total Stockholder Equity = 1.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.57% (Net Income 162.8m / Total Assets 3.63b)
RoE = 10.45% (Net Income TTM 162.8m / Total Stockholder Equity 1.56b)
RoCE = 9.74% (EBIT 267.9m / Capital Employed (Equity 1.56b + L.T.Debt 1.19b))
RoIC = 7.37% (NOPAT 202.6m / Invested Capital 2.75b)
WACC = 5.09% (E(2.11b)/V(3.55b) * Re(8.06%) + D(1.44b)/V(3.55b) * Rd(1.00%) * (1-Tc(0.24)))
Discount Rate = 8.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 8.11%
[DCF Debug] Terminal Value 85.48% ; FCFF base≈315.4m ; Y1≈290.7m ; Y5≈261.6m
Fair Price DCF = 759.0 (EV 7.88b - Net Debt 557.8m = Equity 7.32b / Shares 9.65m; r=5.90% [WACC]; 5y FCF grow -9.81% → 2.90% )
EPS Correlation: -20.68 | EPS CAGR: -38.58% | SUE: -1.74 | # QB: 0
Revenue Correlation: -7.37 | Revenue CAGR: 0.67% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.08 | Chg30d=-0.013 | Revisions Net=-1 | Analysts=4
EPS current Year (2026-09-30): EPS=2.78 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=+1.8% | Growth Revenue=+0.1%
EPS next Year (2027-09-30): EPS=2.97 | Chg30d=-0.002 | Revisions Net=-1 | Growth EPS=+6.7% | Growth Revenue=+2.0%